Skip to main content
Fig. 2 | Antimicrobial Resistance & Infection Control

Fig. 2

From: Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients

Fig. 2

Ceftolozane/tazobactam and ceftazidime/avibactam susceptibility results of subgroups of isolates by phenotypic or genotypic carbapenemase testing results from patients in the ICU (A) or non-ICU (B). These data can guide clinicians to rational antimicrobial selection while awaiting susceptibility testing results for ceftolozane/tazobactam and/or ceftazidime/avibactam. Ruling out carbapenemase can inform clinicians that either ceftolozane/tazobactam or ceftazidime/avibactam is likely active and thus be rational selections. Conversely, non-specific detection phenotypically of a carbapenemase is associated with poor susceptibility to either agent suggesting alternative therapies. Molecular detection of specific carbapenemase classes can further refine agent selection

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us